Monoclonal Antibody Discovery and Research Report 2022-2032 - Growing Demand for Monoclonal Antibodies for Cancer Treatments
June 13, 2023 10:38 ET
|
Research and Markets
Dublin, June 13, 2023 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Discovery and Analysis Market Report 2022-2032" report has been added to ResearchAndMarkets.com's offering.Overall world revenue...
Global Monoclonal Antibody Partnering Terms and Agreements Trends Report 2023
June 13, 2023 04:58 ET
|
Research and Markets
Dublin, June 13, 2023 (GLOBE NEWSWIRE) -- The "Global Monoclonal Antibody Partnering Terms and Agreements 2016 to 2023" report has been added to ResearchAndMarkets.com's offering.The Global...
Global Monoclonal Antibody Therapeutics Market Report 2023: Sector is Expected to Reach $534.2 Billion by 2030 at a CAGR of 12.7%
June 08, 2023 06:18 ET
|
Research and Markets
Dublin, June 08, 2023 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Therapeutics Market, By Source, by Application, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity...
Organ Transplant Rejection Medication Market to Surpass USD 7.0 Billion by 2031, Propelled by Remarkable CAGR of 3.9% | Transparency Market Research
June 07, 2023 13:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 07, 2023 (GLOBE NEWSWIRE) -- The global organ transplant rejection medication market is estimated to flourish at a CAGR of 3.9% from 2023 to 2031. According...
BioNTech und OncoC4 präsentieren positive Phase-1/2-Daten für Antikörperkandidaten BNT316/ONC-392 bei schwer behandelbarem nicht-kleinzelligen Lungenkarzinom auf ASCO-Jahrestagung
June 02, 2023 06:45 ET
|
BioNTech SE
BNT316/ONC-392 ist ein innovativer monoklonaler anti-CTLA-4-Antikörperkandidat, der gemeinsam von BioNTech und OncoC4 als Mono- oder Kombinationstherapie zur Behandlung verschiedener solider...
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
June 02, 2023 06:45 ET
|
BioNTech SE
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications,...
Dyadic to Participate at Upcoming Events in June
June 01, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
China Cancer Antibodies Market Trends & Clinical Trials Analysis Report 2023: 30+ Cancer Antibodies Commercially Approved and More than 800 in Clinical Trials
May 31, 2023 05:03 ET
|
Research and Markets
Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "China Cancer Antibodies Market Trends & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering. The current...
Global Western Blotting Market Report 2023: Increasing Adoption of Organic Growth Strategies Drives Growth
May 29, 2023 10:03 ET
|
Research and Markets
Dublin, May 29, 2023 (GLOBE NEWSWIRE) -- The "Western Blotting Market, By Product Type Electrophoresis Blotting Systems, Reagents & Kits, Fluorescent Reagents, Antibodies, Buffer Kits, Transfer...
Global CD137 Antibodies Clinical Trials Research Report 2023: Increasing Investment in the Cancer Therapeutics Domain & Involvement of Prominent Companies Driving the CD137 Market
May 22, 2023 04:08 ET
|
Research and Markets
Dublin, May 22, 2023 (GLOBE NEWSWIRE) -- The "Global CD137 Antibodies Clinical Trials & Market Trends Insight 2023" report has been added to ResearchAndMarkets.com's offering. The therapeutic...